| answer text |
<p>The UK is committed to rapid equitable access to safe and effective vaccines, and
is playing a leading role in financing the global effort, and identifying solutions
that ensure affordable access for all.</p><p>The UK Government does not consider waiving
intellectual property (IP) rights to be an appropriate course of action in boosting
the manufacturing of safe, effective, and quality vaccines. The existing intellectual
property framework has mobilised research and development to deliver a host of new
medicines and technologies to detect, treat, and defend against COVID-19. The incentives
and access mechanisms provided by the IP framework have been integral to this success,
without which we would not have seen the impressive surge of research and development,
and the unprecedented scaling up of production.</p>
|
 |
